• [email protected]
  • +971 507 888 742
Submit Manuscript
SciAlert
  • Home
  • Journals
  • Information
    • For Authors
    • For Referees
    • For Librarian
    • For Societies
  • Contact
  1. International Journal of Pharmacology
  2. Vol 10 (4), 2014
  3. 231-236
  • Online First
  • Current Issue
  • Previous Issues
  • More Information
    Aims and Scope Editorial Board Guide to Authors Article Processing Charges
    Submit a Manuscript

International Journal of Pharmacology

Year: 2014 | Volume: 10 | Issue: 4 | Page No.: 231-236
DOI: 10.3923/ijp.2014.231.236

Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Article Trend



Total views 44

Authors


Liping Wan

Country: China

Chun Wang

Country: China

Lin Liu

Country: China

Xiaoqiong Tang

Country: China

Jinghua Wang

Country: China

Yue Guan

Country: China

Ming Jiang

Country: China

Xianlin Duan

Country: China

Xiaoyan Ke

Country: China

Hongmei Jing

Country: China

Jiong Hu

Country: China

Ling Wang

Country: China

Yuming Li

Country: China

Li Geng

Country: China

Keywords


  • hematologic malignancy
  • invasive fungal disease
  • Micafungin
  • neutropenia
  • prophylaxis
Research Article

Efficacy and Safety of Micafungin as Prophylaxis for Invasive Fungal Disease in Neutropenic Patients with Hematologic Malignancies

Liping Wan, Chun Wang, Lin Liu, Xiaoqiong Tang, Jinghua Wang, Yue Guan, Ming Jiang, Xianlin Duan, Xiaoyan Ke, Hongmei Jing, Jiong Hu, Ling Wang, Yuming Li and Li Geng
Invasive Fungal Disease (IFD) is a major cause of death in severe neutropenic patients with hematologic malignancies. Micafungin, a new echinocandin antifungal drug, is effective in treating IFD. However, the efficacy and safety of micafungin in preventing IFD in severe neutropenic patients with hematologic malignancies have not been demonstrated. A prospective and multicenter clinical study was conducted to evaluate the efficacy and safety of micafungin as prophylaxis for IFD. Micafungin 50 mg daily was administered intravenously to 117 high-risk patients with hematologic malignancies undergoing intensive chemotherapy or Hematopoietic Stem Cell Transplantation (HSCT), for a median of 24 days. Successful prophylaxis (no proven, probable or possible IFD up to 1 week after the end of prophylactic treatment) was achieved in 88.54% patients. No patient developed proven IFD during treatment and only 2.08% had probable IFD and 9.38% possible IFD. Micafungin potentially accounted for adverse events in 6.84% of patients. No severe adverse events attributable to micafungin were seen. Micafungin 50 mg daily is a promising prophylactic antifungal therapy for neutropenic patients with hematologic malignancies.
PDF Fulltext XML References Citation

How to cite this article

Liping Wan, Chun Wang, Lin Liu, Xiaoqiong Tang, Jinghua Wang, Yue Guan, Ming Jiang, Xianlin Duan, Xiaoyan Ke, Hongmei Jing, Jiong Hu, Ling Wang, Yuming Li and Li Geng, 2014. Efficacy and Safety of Micafungin as Prophylaxis for Invasive Fungal Disease in Neutropenic Patients with Hematologic Malignancies. International Journal of Pharmacology, 10: 231-236.

DOI: 10.3923/ijp.2014.231.236

URL: https://scialert.net/abstract/?doi=ijp.2014.231.236

Leave a Comment


Your email address will not be published. Required fields are marked *

Useful Links

  • Journals
  • For Authors
  • For Referees
  • For Librarian
  • For Socities

Contact Us

Office Number 1128,
Tamani Arts Building,
Business Bay,
Deira, Dubai, UAE

Phone: +971 507 888 742
Email: [email protected]

About Science Alert

Science Alert is a technology platform and service provider for scholarly publishers, helping them to publish and distribute their content online. We provide a range of services, including hosting, design, and digital marketing, as well as analytics and other tools to help publishers understand their audience and optimize their content. Science Alert works with a wide variety of publishers, including academic societies, universities, and commercial publishers.

Follow Us
© Copyright Science Alert. All Rights Reserved